338 related articles for article (PubMed ID: 38818470)
21. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis of benign metastasizing leiomyoma: a review.
Awonuga AO; Shavell VI; Imudia AN; Rotas M; Diamond MP; Puscheck EE
Obstet Gynecol Surv; 2010 Mar; 65(3):189-95. PubMed ID: 20214834
[TBL] [Abstract][Full Text] [Related]
23. [Differential diagnosis of cellular leiomyomas and leiomyoplastic sarcomas].
Cupr Z; Rohanova M; Holle V; Sikula M
Zentralbl Gynakol; 1972 Jan; 94(3):101-8. PubMed ID: 5017233
[No Abstract] [Full Text] [Related]
24. Literature review of outcomes and prevalence and case report of leiomyosarcomas and non-typical uterine smooth muscle leiomyoma tumors treated with uterine artery embolization.
Kainsbak J; Hansen ES; Dueholm M
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():130-7. PubMed ID: 26117442
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Shanes ED; Friedman LA; Mills AM
Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
[TBL] [Abstract][Full Text] [Related]
26. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
George S; Barysauskas C; Serrano C; Oduyebo T; Rauh-Hain JA; Del Carmen MG; Demetri GD; Muto MG
Cancer; 2014 Oct; 120(20):3154-8. PubMed ID: 24923260
[TBL] [Abstract][Full Text] [Related]
27. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F
Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710
[TBL] [Abstract][Full Text] [Related]
28. Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas.
Fernandez-Flores A; Monteagudo C
Ann Diagn Pathol; 2016 Oct; 24():25-9. PubMed ID: 27649950
[TBL] [Abstract][Full Text] [Related]
29. Intraoperative Frozen Section Biopsy of Uterine Smooth Muscle Tumors: A Clinicopathologic Analysis of 112 Cases With Emphasis on Potential Diagnostic Pitfalls.
Lok J; Tse KY; Lee EYP; Wong RWC; Cheng ISY; Chan ANH; Leung CKL; Cheung ANY; Ip PPC
Am J Surg Pathol; 2021 Sep; 45(9):1179-1189. PubMed ID: 34074809
[TBL] [Abstract][Full Text] [Related]
30. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
31. [Malignant neoplasms of the uterus in women treated with uterine artery embolization for presumed leiomyoma--description of three cases].
Gajewska M; Panek G
Ginekol Pol; 2013 Mar; 84(3):229-33. PubMed ID: 23700853
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical detection of promyelocytic leukemia zinc finger and histone 1.5 in uterine leiomyosarcoma and leiomyoma.
Momeni M; Kalir T; Farag S; Kinoshita Y; Roman TY; Chuang L; Fishman DA; Burstein DE
Reprod Sci; 2014 Sep; 21(9):1171-6. PubMed ID: 24784718
[TBL] [Abstract][Full Text] [Related]
33. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
[TBL] [Abstract][Full Text] [Related]
34. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas.
Mittal KR; Chen F; Wei JJ; Rijhvani K; Kurvathi R; Streck D; Dermody J; Toruner GA
Mod Pathol; 2009 Oct; 22(10):1303-11. PubMed ID: 19633649
[TBL] [Abstract][Full Text] [Related]
35. Serum microRNA profile enables preoperative diagnosis of uterine leiomyosarcoma.
Yokoi A; Matsuzaki J; Yamamoto Y; Tate K; Yoneoka Y; Shimizu H; Uehara T; Ishikawa M; Takizawa S; Aoki Y; Kato K; Kato T; Ochiya T
Cancer Sci; 2019 Dec; 110(12):3718-3726. PubMed ID: 31599471
[TBL] [Abstract][Full Text] [Related]
36. DNA fragmentation factors 40 and 45 (DFF40/DFF45) and B-cell lymphoma 2 (Bcl-2) protein are underexpressed in uterine leiomyosarcomas and may predict survival.
Banas T; Pitynski K; Okon K; Czerw A
Onco Targets Ther; 2017; 10():4579-4589. PubMed ID: 29075126
[TBL] [Abstract][Full Text] [Related]
37. Mass lesions of the myometrium: interpretation and management of unexpected pathology.
Porter AE; Kho KA; Gwin K
Curr Opin Obstet Gynecol; 2019 Oct; 31(5):349-355. PubMed ID: 31425175
[TBL] [Abstract][Full Text] [Related]
38. Molecular differential diagnosis of uterine leiomyomas and leiomyosarcomas.
Mas A; Simón C
Biol Reprod; 2019 Dec; 101(6):1115-1123. PubMed ID: 30184111
[TBL] [Abstract][Full Text] [Related]
39. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
[TBL] [Abstract][Full Text] [Related]
40. [The differential diagnosis between uterine leiomyosarcoma and the special subtypes of leiomyoma].
Zhu XQ; Shi YF; Cheng XD; Wu YZ
Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(16):1419-21. PubMed ID: 14521746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
